Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study

Progression and treatment rates using an active surveillance protocol incorporating image‐guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable‐risk prostate cancer

“…Neither a positive mpMRI lesion nor an initial Grade Group 2 diagnosis predicted progression or conversion to active treatment which is in contrast to other studies [31][32][33]. We did observe that men with a previous negative biopsy appeared less likely to progress, which supports the findings of a recent large Danish study that reported extremely low rates of prostate cancer mortality [0.7-3.6%] from a retrospective database review of men with first negative biopsies over a 20-year follow-up period, underscoring the indolent nature of many of these tumours [34].…”

The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naïve men

“…Of concern was the recent finding that a man with a negative TRUS biopsy had a risk of death from prostate cancer of 5.2%, which is greater than the lifetime risk of prostate cancer death for the average man [16,17].…”

Using prognosis to guide early detection and treatment selection in non‐metastatic prostate cancer

“…Klemann et al have shown that in men with initially negative investigations (using traditional transrectal biopsies) the risk of death from undetected disease is very low. In this large population study, the prostate cancer‐specific mortality was only 5% vs nearly 60% for other cause mortality over 20 years .…”

“…Klemann et al have shown that in men with initially negative investigations (using traditional transrectal biopsies) the risk of death from undetected disease is very low. In this large population study, the prostate cancer‐specific mortality was only 5% vs nearly 60% for other cause mortality over 20 years . Furthermore, long‐term active surveillance programmes have reported high rates of disease‐specific survival and low rates of progression, even in men with intermediate‐risk disease .…”